



**PAUL  
CAPITAL**

### **Paul Capital Promotes Andrew Rubinstein To Partner**

**NEW YORK, NY** – January 4, 2010 – Paul Capital today announced that Andrew Rubinstein has been promoted to Partner. Based in Paul Capital’s New York office, Mr. Rubinstein’s primary responsibility is negotiating, structuring and executing royalty and revenue interest investments in the United States and internationally.

“Andrew’s expertise and innovation has been integral to the successful execution of a number of transactions,” said Walter Flamenbaum, M.D., a Partner of Paul Capital. “The combination of his financial, operating and transaction expertise, in the United States and internationally, is an asset that allows us to structure flexible transactions that provide our portfolio companies with the growth capital they need while also creating attractive investment opportunities for Paul Capital Healthcare. We are very pleased to have him as a Partner.”

“The biotechnology and pharmaceutical industries are highly capital intensive and there is a growing recognition in these industries that royalty and revenue streams can be leveraged to meet these capital needs”, said Mr. Rubinstein. “Paul Capital, with its experienced team of healthcare investment professionals, is on the leading edge of royalty and revenue interest financing and I am pleased to be a part of this highly capable team.”

Mr. Rubinstein joined Paul Capital in 2007. Prior to joining Paul Capital, he was CEO of Microban International, Ltd. a multinational licensing business focused on antimicrobial technologies. Mr. Rubinstein had previously worked as an investment banker at Merrill Lynch & Co. in the Financial Sponsors Group. He earned a B.A. from the University of Pennsylvania, a J.D. from New York University School of Law, and an M.B.A. from New York University Stern School of Business where he graduated with honors as a Beta Gamma Sigma Scholar.

#### **About Paul Capital Healthcare and Paul Capital**

Through its funds, Paul Capital Healthcare is one of the largest dedicated healthcare investors globally, with more than \$1.6 billion in equity capital commitments and debt facilities under management. Combined, the Paul Capital Healthcare funds have invested more than \$1 billion in the pharmaceutical, biotechnology, and medical device sectors. These investments are focused on commercial stage companies and products, and consist of investments in the form of royalties, revenue interests, debt and equity. Additional information on Paul Capital Healthcare can be found at [www.paulcapitalhealthcare.com](http://www.paulcapitalhealthcare.com). Paul Capital manages nearly \$7.3 billion in capital commitments for its three investment platforms, which include Paul Capital Healthcare, Private Equity Secondary Funds and

Top Tier Fund-of-Funds. The firm has offices in New York, San Francisco, Paris, London, Hong Kong, and São Paulo.

**Contact Information:**

**Media Inquiries/Lazar Partners**

Susan Rood

Tel: +1 - 212-843-0210

Email: [srood@lazarpartners.com](mailto:srood@lazarpartners.com)